Board of Directors

Ryan Saadi, MD, MPH

Chief Executive Officer

View Bio

Kirti Desai

Chief Financial Officer

Dr. Curtis Patton

View Bio

Kevin McGrath

View Bio

Scientific Advisory Board

Neal Flomenberg, MD Chairman, Scientific Advisory Board

View Bio

© 2020 Tevogen Bio. All Rights Reserved.

Ryan Saadi, M.D., M.P.H., is Chief Executive Officer and co-founder of Tevogen Bio. Ryan also serves as an adviser to Quantaira Health, a health technology company aims to advance ventilator technologies for COVID-19 patients. As Managing Director and Executive Advisor of the Center for Market Access and Medical Innovation, Ryan leads a cross-sector educational initiative which seeks to promote sustainable medical innovation, improve patient access, inform policy-making, and foster talent development.

As a renowned innovator in the world of healthcare and a leading expert in global health policy, market access, clinical development, and research, Ryan actively partners, speaks and advises on various healthcare matters with a number of organizations from the private sector (life sciences companies), the public sector (including at the state, federal and global level), academia, and the not-for-profit sectors.

Ryan points to his unyielding passion for public health, his unique ability to unite normally siloed parties under a common cause, and his “irrational optimism” as the driving force behind his success and the recent formation of Tevogen Bio.

Previously, Ryan spent nearly three decades in healthcare, in leadership roles within hospital administration, managed care, and life sciences. He has been recognized multiple times for his unique leadership approach, including being named among the Most Inspiring Leaders in the Life Sciences Industry. Ryan is an accomplished graduate of Harvard Business School Executive Education Program, Yale School of Medicine, and Dhaka Medical College.

Dr. Curtis Patton, Professor Emeritus at Yale University, is a world renowned scientist and Public Health expert. He has served in a variety of administrative capacities including Division Head, Epidemiology of Microbial Diseases and Acting Head of Global Health. He has also served as the Director of International Medical Studies and Chair of the Committee on International Health at Yale University.

Mr. McGrath has 25 years of experience helping biopharmaceutical companies develop and enhance their market access and value evidence capabilities to support the launch of innovative medicines. He is a graduate of Princeton University.

In addition to his professional experience, Mr. McGrath is dedicated to volunteerism, providing educational, athletic and cultural enrichment opportunities to youth and underserved communities. He is inspired by Tevogen’s mission of developing curative therapies at an affordable price and it’s potential to dramatically improve the global public health landscape.

Dr. Flomenberg is Professor and Chair of the Department of Medical Oncology and Deputy Director of Jefferson’s Sidney Kimmel Cancer Center. His career has focused on the care of patients with blood cancers, particularly those undergoing bone marrow or peripheral blood stem cell transplants. His laboratory and clinical research efforts have focused on improving our understanding of the challenges these patients face and developing innovative solutions to these problems. He has authored more than 175 peer reviewed publications.

Amongst others, his most significant scientific accomplishments include:

His laboratory work was focused on cellular immunology, immunogenetics, and histocompatibility. He served as the organizer/leader of the cellular section of the Tenth International Histocompatibility Workshop.

In addition to his research, Dr. Flomenberg maintains an active practice and has been continuously listed in Philadelphia Magazine’s Top Doctors in Philadelphia and Castle Connolly’s America’s Top Doctors over the last 15 years. Under his leadership, Jefferson’s Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program, and has launched efforts to expand home chemotherapy administration and other cutting-edge care delivery models.

Dr. Flomenberg has been the recipient of numerous awards including: